BRPI0921313A2 - composição farmaucêutica - Google Patents
composição farmaucêuticaInfo
- Publication number
- BRPI0921313A2 BRPI0921313A2 BRPI0921313A BRPI0921313A BRPI0921313A2 BR PI0921313 A2 BRPI0921313 A2 BR PI0921313A2 BR PI0921313 A BRPI0921313 A BR PI0921313A BR PI0921313 A BRPI0921313 A BR PI0921313A BR PI0921313 A2 BRPI0921313 A2 BR PI0921313A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08105817 | 2008-11-18 | ||
EP09100312 | 2009-06-02 | ||
PCT/EP2009/065271 WO2010057870A1 (en) | 2008-11-18 | 2009-11-17 | Prolonged release formulations comprising an 2 -oxo- 1 -pyrrolidine derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0921313A2 true BRPI0921313A2 (pt) | 2015-12-29 |
Family
ID=41381618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0921313A BRPI0921313A2 (pt) | 2008-11-18 | 2009-11-17 | composição farmaucêutica |
Country Status (18)
Country | Link |
---|---|
US (3) | US10172805B2 (pt) |
EP (1) | EP2358360B1 (pt) |
JP (2) | JP5954890B2 (pt) |
KR (1) | KR101689688B1 (pt) |
CN (2) | CN104208714A (pt) |
AU (1) | AU2009317280B2 (pt) |
BR (1) | BRPI0921313A2 (pt) |
CA (1) | CA2741041C (pt) |
DK (1) | DK2358360T3 (pt) |
EA (1) | EA019572B1 (pt) |
ES (1) | ES2602604T3 (pt) |
HK (1) | HK1159503A1 (pt) |
HU (1) | HUE032275T2 (pt) |
IL (1) | IL212447A (pt) |
MX (1) | MX339852B (pt) |
PL (1) | PL2358360T3 (pt) |
PT (1) | PT2358360T (pt) |
WO (1) | WO2010057870A1 (pt) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107243007A (zh) | 2008-10-16 | 2017-10-13 | 约翰斯.霍普金斯大学 | 改善认知功能的方法和组合物 |
HUE032275T2 (en) * | 2008-11-18 | 2017-09-28 | Ucb Biopharma Sprl | Sustained release formulations containing a 2-oxo-pyrrolidine derivative |
WO2011107855A2 (en) * | 2010-03-04 | 2011-09-09 | Torrent Pharmaceuticals Limited | Sustained release oral liquid suspension dosage form |
EP2563339A1 (en) * | 2010-04-29 | 2013-03-06 | Lupin Limited | Controlled release pharmaceutical compositions of brivaracetam |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
EP3827820A1 (en) | 2013-03-15 | 2021-06-02 | The Johns Hopkins University | Brivaracetam for improving cognitive function |
CN112843005B (zh) | 2015-05-22 | 2023-02-21 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
EP3127539A1 (en) * | 2015-08-03 | 2017-02-08 | Latvian Institute Of Organic Synthesis | Use of 2-(5s-methyl-2-oxo-4r-phenyl-pyrrolidin-1-yl)-acetamide in the treatment of seizures |
WO2017117569A1 (en) | 2015-12-30 | 2017-07-06 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
CN111407738A (zh) * | 2020-04-03 | 2020-07-14 | 江苏艾立康药业股份有限公司 | 一种布立西坦控释制剂及其制备方法 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6327424A (ja) | 1986-07-17 | 1988-02-05 | Shionogi & Co Ltd | 徐放性製剤およびその製造法 |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
US5622716A (en) | 1987-02-20 | 1997-04-22 | Farmarc Nederland B.V. | Process for preparing a retard product containing diltiazem for a single daily administration |
US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
EP0452862B1 (en) * | 1990-04-18 | 1995-07-19 | Asahi Kasei Kogyo Kabushiki Kaisha | Spherical seed cores, spherical granules and process for production thereof |
JP2558396B2 (ja) * | 1990-06-28 | 1996-11-27 | 田辺製薬株式会社 | 放出制御型製剤 |
JPH10182438A (ja) * | 1991-03-07 | 1998-07-07 | Takeda Chem Ind Ltd | 有核散剤 |
DE19630035A1 (de) | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
US6919373B1 (en) * | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
US5997905A (en) * | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
US8168170B2 (en) * | 2002-10-03 | 2012-05-01 | The Procter And Gamble Company | Compositions having an inner core and at least three surrounding layers |
CA2507685A1 (en) | 2002-11-28 | 2004-06-10 | Themis Laboratories Private Limited | Process for manufacturing sustained release microbeads containing venlafaxine hci |
DE10353186A1 (de) * | 2003-11-13 | 2005-06-16 | Röhm GmbH & Co. KG | Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz |
SI21637A (sl) * | 2003-12-23 | 2005-06-30 | LEK farmacevtska dru�ba d.d. | Farmacevtska oblika z nadzorovanim sproščanjem |
WO2006088864A1 (en) * | 2005-02-16 | 2006-08-24 | Elan Pharma International Limited | Controlled release compositions comprising levetiracetam |
US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
BRPI0609598A2 (pt) * | 2005-03-29 | 2010-04-20 | Roehm Gmbh | forma farmacêutica multiparticulada compreendendo péletes com uma substáncia possuindo um efeito modular em relação à liberação de ingrediente ativo |
WO2006125074A1 (en) * | 2005-05-17 | 2006-11-23 | Brown University Research Foundation | Drug delivery formulations for targeted delivery |
US20070264346A1 (en) * | 2006-02-16 | 2007-11-15 | Flamel Technologies | Multimicroparticulate pharmaceutical forms for oral administration |
FR2897267A1 (fr) | 2006-02-16 | 2007-08-17 | Flamel Technologies Sa | Formes pharmaceutiques multimicroparticulaires pour administration per os |
US8211936B2 (en) | 2006-06-08 | 2012-07-03 | Ucb Pharma, S.A. | Co-crystals of pyrrolidinones |
DE102006035549A1 (de) * | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
JP5513113B2 (ja) * | 2006-08-31 | 2014-06-04 | アプタリス ファーマテック,インコーポレイテッド | 弱塩基性薬剤の固溶体を含む薬剤送達システム |
CN101801356B (zh) | 2007-09-21 | 2016-10-19 | 赢创罗姆有限公司 | 耐受乙醇影响的非阿片类的pH依赖性受控释放的药物组合物 |
WO2009102964A2 (en) * | 2008-02-14 | 2009-08-20 | Nordson Corporation | Apparatus for testing containers, tray for holding cylinders and suction-basedchuck for robotic arm |
HUE032275T2 (en) * | 2008-11-18 | 2017-09-28 | Ucb Biopharma Sprl | Sustained release formulations containing a 2-oxo-pyrrolidine derivative |
PL2358361T3 (pl) * | 2008-11-18 | 2017-02-28 | Ucb Biopharma Sprl | Preparaty o przedłużonym uwalnianiu zawierające pochodną 2-okso-1-pirolidyny |
-
2009
- 2009-11-17 HU HUE09751938A patent/HUE032275T2/en unknown
- 2009-11-17 WO PCT/EP2009/065271 patent/WO2010057870A1/en active Application Filing
- 2009-11-17 US US13/129,114 patent/US10172805B2/en active Active
- 2009-11-17 PL PL09751938T patent/PL2358360T3/pl unknown
- 2009-11-17 EA EA201100752A patent/EA019572B1/ru unknown
- 2009-11-17 JP JP2011543763A patent/JP5954890B2/ja active Active
- 2009-11-17 EP EP09751938.3A patent/EP2358360B1/en active Active
- 2009-11-17 CN CN201410407641.9A patent/CN104208714A/zh active Pending
- 2009-11-17 MX MX2011004816A patent/MX339852B/es active IP Right Grant
- 2009-11-17 ES ES09751938.3T patent/ES2602604T3/es active Active
- 2009-11-17 CN CN200980145828.3A patent/CN102215829B/zh active Active
- 2009-11-17 CA CA2741041A patent/CA2741041C/en active Active
- 2009-11-17 AU AU2009317280A patent/AU2009317280B2/en active Active
- 2009-11-17 PT PT97519383T patent/PT2358360T/pt unknown
- 2009-11-17 DK DK09751938.3T patent/DK2358360T3/en active
- 2009-11-17 BR BRPI0921313A patent/BRPI0921313A2/pt not_active IP Right Cessation
- 2009-11-17 KR KR1020117013972A patent/KR101689688B1/ko active IP Right Grant
-
2011
- 2011-04-26 IL IL212447A patent/IL212447A/en active IP Right Grant
-
2012
- 2012-01-03 HK HK12100018.4A patent/HK1159503A1/xx unknown
-
2015
- 2015-03-30 JP JP2015068416A patent/JP2015120756A/ja active Pending
-
2019
- 2019-01-07 US US16/241,184 patent/US20190142759A1/en not_active Abandoned
- 2019-07-12 US US16/509,919 patent/US20200085754A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2012509357A (ja) | 2012-04-19 |
JP2015120756A (ja) | 2015-07-02 |
KR20110089182A (ko) | 2011-08-04 |
ES2602604T3 (es) | 2017-02-21 |
EA201100752A1 (ru) | 2012-01-30 |
AU2009317280A1 (en) | 2010-05-27 |
US20200085754A1 (en) | 2020-03-19 |
MX339852B (es) | 2016-06-15 |
US10172805B2 (en) | 2019-01-08 |
HK1159503A1 (en) | 2012-08-03 |
CA2741041C (en) | 2015-01-13 |
CN102215829B (zh) | 2014-12-10 |
HUE032275T2 (en) | 2017-09-28 |
MX2011004816A (es) | 2011-05-30 |
KR101689688B1 (ko) | 2016-12-26 |
PL2358360T3 (pl) | 2017-02-28 |
CN102215829A (zh) | 2011-10-12 |
US20190142759A1 (en) | 2019-05-16 |
IL212447A0 (en) | 2011-06-30 |
EA019572B1 (ru) | 2014-04-30 |
AU2009317280B2 (en) | 2014-03-06 |
US20110250282A1 (en) | 2011-10-13 |
IL212447A (en) | 2016-10-31 |
CN104208714A (zh) | 2014-12-17 |
EP2358360A1 (en) | 2011-08-24 |
DK2358360T3 (en) | 2016-12-12 |
JP5954890B2 (ja) | 2016-07-20 |
CA2741041A1 (en) | 2010-05-27 |
PT2358360T (pt) | 2016-11-15 |
WO2010057870A1 (en) | 2010-05-27 |
EP2358360B1 (en) | 2016-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LTPA2018014I1 (lt) | Farmacinė kompozicija 514 | |
LTC2140867I2 (lt) | Farmacinė kompozicija | |
SMT201600259B (it) | Composizioni farmaceutiche antibatteriche | |
SMT201700095B (is) | Composizioni farmaceutiche per inalazione | |
BRPI0721651A2 (pt) | Composição farmacêutica | |
DK3097925T3 (da) | Farmaceutisk sammensætning | |
BRPI0920521A2 (pt) | combinação farmacêutica | |
BRPI1004940A2 (pt) | composição farmacêutica | |
DE602008002756D1 (de) | Bauzusammensetzung | |
BRPI0906749A2 (pt) | Composição | |
BRPI0913808A2 (pt) | composição | |
RU2493831C3 (ru) | Фармацевтические композиции | |
BRPI1015939A2 (pt) | composição farmacêutica | |
DK2120884T3 (da) | Farmaceutisk sammensætning | |
IT1392101B1 (it) | Composizione comprendente isoflavoni | |
BRPI0917231A2 (pt) | composição | |
DK2285413T3 (da) | Farmaceutisk sammensætning | |
BRPI1012539A2 (pt) | composições farmacêuticas | |
BRPI0921313A2 (pt) | composição farmaucêutica | |
IT1394400B1 (it) | Composizioni farmaceutiche | |
BRPI0921654A2 (pt) | formulação farmacêutica | |
DK2285357T3 (da) | Farmaceutisk sammensætning omfattende brivaracetam | |
DK2391349T3 (da) | Farmaceutisk sammensætning omfattende 2-oco-1-pyrrolidin-derivater | |
DK2271618T3 (da) | Farmaceutiske forbindelser | |
BRPI0820198A2 (pt) | composições farmacêuticas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2494 DE 23-10-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |